View the diagnostic patents and projects held by faculty of Saint Louis University.
Inventors: Kazuo Okamura, Shuichi Miyaura, Shunji Tomatsu
Summary: A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.
U.S. 7,951,545 - Applies to Type I, II, III, VI, or VII mucopolysaccharidosis detection
U.S. 8,003,337 - Applies to Type IV mucopolysaccharidosis detection
Manager: Malcolm Townes, firstname.lastname@example.org
Inventors: Hans Peter Zassenhaus
Summary: Disclosed are methods and compositions for the ultrasensitive detection of oligonucleotides, proteins, protein complexes, biomolecules, and infectious agents using a peroxidase driven deposition of substrates onto interferometry capable biosensors, coupled to the specific recognition of the target molecules. More specifically, methods are disclosed to specifically immobilize biological target molecules onto the surface of interferometry capable biosensors and to associate the target molecules with peroxidase enzymes. Through the peroxidase driven deposition of substrates onto the interferometry capable biosensors there is the ability to achieve ultrasensitive detection and quantification of specific target molecules.
Patent: U.S. patent pending
Manager: Stephanie Kimzey, MBA
Inventors: David A. Ford
Summary: The present invention provides diagnostic methods for characterizing an individual's risk for developing or having an adverse coronary event. More particular, the present invention is generally directed to characterizing an individual's risk for developing or having an adverse coronary event by determining the presence of myeloperoxidase-derived chlorinated lipids in body fluids and tissues. The invention is predicated upon the discovery that tissue plasmalogens are targeted by hypochlorous acid produced by activated neutrophil-derived myeloperoxidase (MPO). This reaction leads to the production of a family of chlorinated lipids useful in the diagnostic method of the present invention and that function as a better prognostic indicator of future adverse coronary events than either MPO or C-reactive protein (CRP). Chlorinated lipids are a catalytic product of MPO activity (i.e., one molecule of MPO can produce hundreds to thousands of molecules of chlorinated lipids) making their dynamic range in plasma much greater than that of MPO. Further, in comparison to CRP, chlorinated lipids are a much more specific marker of inflammation. The present invention also provides kits that include assays for determining the presence or levels of myeloperoxidase-derived chlorinated lipids in body tissues of fluids.
Patent: U.S. 8,137,978
Manager: Stephanie Kimzey, MBA